These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8113839)

  • 1. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome.
    Foss FM; Koc Y; Stetler-Stevenson MA; Nguyen DT; O'Brien MC; Turner R; Sausville EA
    J Clin Oncol; 1994 Feb; 12(2):326-35. PubMed ID: 8113839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-7 is a growth factor for Sézary lymphoma cells.
    Dalloul A; Laroche L; Bagot M; Mossalayi MD; Fourcade C; Thacker DJ; Hogge DE; Merle-Béral H; Debré P; Schmitt C
    J Clin Invest; 1992 Sep; 90(3):1054-60. PubMed ID: 1381718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells.
    Döbbeling U; Dummer R; Laine E; Potoczna N; Qin JZ; Burg G
    Blood; 1998 Jul; 92(1):252-8. PubMed ID: 9639524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
    Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
    J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 2 production and interleukin 2 receptor expression by human immature leukemic T cells.
    Sahraoui Y; Allouche M; Ammar A; Spanakis E; Clemenceau C; Jasmin C; Perraki M; Varela-Millot C; Georgoulias V
    Leukemia; 1992 Oct; 6(10):1025-35. PubMed ID: 1405755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.
    van der Fits L; Out-Luiting JJ; van Leeuwen MA; Samsom JN; Willemze R; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Feb; 132(2):440-7. PubMed ID: 21938013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
    Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
    J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
    Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
    Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD7-positive Sézary syndrome with a Th1 cytokine profile.
    Yagi H; Tokura Y; Furukawa F; Takigawa M
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):368-74. PubMed ID: 8655729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mu-Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome.
    Bénard A; Cavaillès P; Boué J; Chapey E; Bayry J; Blanpied C; Meyer N; Lamant L; Kaveri SV; Brousset P; Dietrich G
    J Invest Dermatol; 2010 May; 130(5):1337-44. PubMed ID: 20107485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
    Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
    Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
    Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
    Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4.
    Showe LC; Fox FE; Williams D; Au K; Niu Z; Rook AH
    J Immunol; 1999 Oct; 163(7):4073-9. PubMed ID: 10491012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-16 as a marker of Sézary syndrome onset and stage.
    Richmond J; Tuzova M; Parks A; Adams N; Martin E; Tawa M; Morrison L; Chaney K; Kupper TS; Curiel-Lewandrowski C; Cruikshank W
    J Clin Immunol; 2011 Feb; 31(1):39-50. PubMed ID: 20878214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12.
    Suchin KR; Cassin M; Gottleib SL; Sood S; Cucchiara AJ; Vonderheid EC; Rook AH
    J Am Acad Dermatol; 2001 Jan; 44(1):28-32. PubMed ID: 11148473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome.
    Abrams JT; Ghosh SK; DeFreitas E
    Cancer Res; 1993 Nov; 53(22):5501-6. PubMed ID: 8221690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.